Planta Med 2011; 77(2): 196-204
DOI: 10.1055/s-0030-1250161
Biological Screening
Original Papers
© Georg Thieme Verlag KG Stuttgart · New York

Inhibition of Advanced Glycation End Product Formation by Medicinal Plant Extracts Correlates with Phenolic Metabolites and Antioxidant Activity

Cory S. Harris1 , 2 , 3 , Louis-Philippe Beaulieu1 , 3 , Marie-Hélène Fraser3 , 4 , 5 , Kristina L. McIntyre1 , 3 , Patrick L. Owen3 , 7 , Louis C. Martineau3 , 6 , Alain Cuerrier3 , 4 , Timothy Johns3 , 5 , 7 , Pierre S. Haddad3 , 6 , Steffany A.L. Bennett2 , 3 , John T. Arnason1 , 3
  • 1Centre for Research in Biopharmaceuticals and Biotechnology, Department of Biology, University of Ottawa, Ottawa, ON, Canada
  • 2Neural Regeneration Laboratory, Ottawa Institute of Systems Biology, Department of Biochemistry, Microbiology, and Immunology, University of Ottawa, Ottawa, ON, Canada
  • 3Canadian Institute of Health Research Team in Aboriginal Anti-diabetic Medicines, Montréal, QC, Canada
  • 4Institut de recherche en biologie végétale et le Jardin botanique de Montréal, Montréal, QC, Canada
  • 5Department of Plant Science, McGill University, Ste. Anne-de-Bellevue, Canada
  • 6Natural Health Products and Metabolic Diseases Laboratory, Department of Pharmacology, Université de Montréal and Montreal Diabetes Research Center, Montréal, QC, Canada
  • 7School of Dietetics and Human Nutrition, McGill University, Ste. Anne-de-Bellevue, QC, Canada
Weitere Informationen

Publikationsverlauf

received April 9, 2010 revised June 22, 2010

accepted June 28, 2010

Publikationsdatum:
17. August 2010 (online)

Abstract

Nonenzymatic formation of advanced glycation end products (AGEs) is accelerated under hyperglycemic conditions characteristic of type 2 diabetes mellitus and contributes to the development of vascular complications. As such, inhibition of AGE formation represents a potential therapeutic target for the prevention and treatment of diabetic complications. In the present study, ethanolic extracts of 17 medicinal plants were assessed for inhibitory effects on in vitro AGE formation through fluorometric and immunochemical detection of fluorescent AGEs and N ε-(carboxymethyl)lysine adducts of albumin (CML‐BSA), respectively. Most extracts inhibited fluorescent AGE formation with IC50 values ranging from 0.4 to 38.6 µg/mL and all extracts reduced CML‐BSA formation but to differing degrees. Results obtained through both methods were highly correlated. Antiglycation activities were positively correlated with total phenolic content, free radical scavenging activity and reduction in malonyldiadehyde levels following oxidation of low-density lipoprotein, but negatively correlated with lag time to formation of conjugated dienes. Together, these results provide evidence that antioxidant phenolic metabolites mediate the antiglycation activity of our medicinal plant collection, a relationship that likely extends to other medicinal and food plants.

References

  • 1 Meetoo D, McGovern P, Safadi R. An epidemiological overview of diabetes across the world.  Br J Nurs. 2007;  16 1002-1007
  • 2 Ulrich P, Cerami A. Protein glycation, diabetes, and aging.  Recent Prog Horm Res. 2001;  56 1-21
  • 3 Ramasamy R. Glycation and RAGE: Common links in the pathogenesis of microvascular and macrovascular complications of diabetes.  Can J Diabetes. 2006;  30 422-429
  • 4 Bierhaus A, Humpert P M, Morcos M, Wendt T, Chavakis T, Arnold B, Stern D M, Nawroth P P. Understanding RAGE, the receptor for advanced glycation end products.  J Mol Med. 2005;  83 876-886
  • 5 Young T K, Reading J, Elias B, O'Neil J D. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress.  CMAJ. 2000;  163 561-566
  • 6 Assembly of First Nations .A First Nations Diabetes Report Card. Part 1: Marking a path to community wellness. Ottawa, ON; Assembly of First Nations 2006: 31
  • 7 Booth G L, Hux J E, Fang J, Chan B T. Time trends and geographic disparities in acute complications of diabetes in Ontario, Canada.  Diabetes Care. 2005;  28 1045-1050
  • 8 Young T K, Reading J, Elias B, O'Neil J D. Type 2 diabetes mellitus in Canada's first nations: status of an epidemic in progress.  CMAJ. 2000;  163 561-566
  • 9 Yu C H, Zinman B. Type 2 diabetes and impaired glucose tolerance in aboriginal populations: a global perspective.  Diabetes Res Clin Pract. 2007;  78 159-170
  • 10 Wu C H, Yen G C. Inhibitory effect of naturally occurring flavonoids on the formation of advanced glycation endproducts.  J Agric Food Chem. 2005;  53 3167-3173
  • 11 Fraser M-H, Cuerrier A, Haddad P, Arnason J T, Owen P, Johns T. Medicinal plants of Cree communities (Québec, Canada): antioxidant activity of plants used to treat type 2 diabetes symptoms.  Can J Physiol Pharmacol. 2007;  85 1200-1214
  • 12 Spoor D C, Martineau L C, Leduc C, Benhaddou-Andaloussi A, Meddah B, Harris C, Burt A, Fraser M H, Coonishish J, Joly E, Cuerrier A, Bennett S A, Johns T, Prentki M, Arnason J T, Haddad P S. Selected plant species from the Cree pharmacopoeia of northern Quebec possess anti-diabetic potential.  Can J Physiol Pharmacol. 2006;  84 847-858
  • 13 Leduc C, Coonishish J, Haddad P, Cuerrier A. Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative ethnobotany.  J Ethnopharmacol. 2006;  105 55-63
  • 14 Harbilas D, Martineau L C, Harris C S, Adeyiwola-Spoor D C A, Saleem A, Lambert J, Caves D, Johns T, Prentki M, Cuerrier A, Arnason J T, Bennett S A L, Haddad P S. Evaluation of the anti-diabetic potential of selected medicinal plant extracts from the Canadian boreal forest used to treat symptoms of diabetes: part II.  Can J Physiol Pharmacol. 2009;  87 479-492
  • 15 Beaulieu L P, Harris C S, Saleem A, Cuerrier A, Haddad P S, Martineau L C, Bennett S A, Arnason J T. Inhibitory effect of the Cree traditional medicine wiishichimanaanh (Vaccinium vitis-idaea) on advanced glycation endproduct formation: identification of active principles.  Phytother Res. 2009;  24 741-747
  • 16 Suzuki R, Okada Y, Okuyama T. Two flavone C-glycosides from the style of Zea mays with glycation inhibitory activity.  J Nat Prod. 2003;  66 564-565
  • 17 Singleton V L, Rossi Jr. J A. Colorimetry of total phenolics with phosphomolybdic-phosphotungistic acid reagents.  Am J Enol Vitic. 1965;  16 144-158
  • 18 Gillespie K M, Chae J M, Ainsworth E A. Rapid measurement of total antioxidant capacity in plants.  Nat Protoc. 2007;  2 867-870
  • 19 Cotelle N, Bernier J L, Catteau J P, Pommery J, Wallet J C, Gaydou E M. Antioxidant properties of hydroxy-flavones.  Free Radic Biol Med. 1996;  20 35-43
  • 20 Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein.  Free Radic Res Commun. 1989;  6 67-75
  • 21 Sobal G, Menzel J, Sinzinger H. Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study.  Prostaglandins Leukot Essent Fatty Acids. 2000;  63 177-186
  • 22 Harris C S, Lambert J, Saleem A, Coonishish J, Martineau L C, Cuerrier A, Haddad P S, Arnason J T, Bennett S A L. Anti-diabetic activity of extracts from needle, bark and cone of Picea glauca: organ specific protection from glucose toxicity and glucose deprivation.  Pharm Biol. 2008;  46 126-134
  • 23 Martineau L C, Muhammad A, Saleem A, Herve J, Harris C S, Arnason J T, Haddad P S. Anti-adipogenic activities of Alnus incana and Populus balsamifera bark extracts, part II: bioassay-guided identification of actives salicortin and oregonin.  Planta Med. 2010;  DOI: 10.1055/s-0029-1240991
  • 24 Saleem A, Harris C S, Asim M, Cuerrier A, Martineau L, Haddad P S, Arnason J T. A RP-HPLC-DAD-APCI/MSD method for the characterisation of medicinal Ericaceae used by the Eeyou Istchee Cree First Nations.  Phytochem Anal. 2010;  DOI: 10.1002/pca.1203
  • 25 Munch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease.  Brain Res Brain Res Rev. 1997;  23 134-143
  • 26 Kilhovd B K, Juutilainen A, Lehto S, Ronnemaa T, Torjesen P A, Hanssen K F, Laakso M. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study.  Diabetologia. 2007;  50 1409-1417
  • 27 Peng X, Cheng K W, Ma J, Chen B, Ho C T, Lo C, Chen F, Wang M. Cinnamon bark proanthocyanidins as reactive carbonyl scavengers to prevent the formation of advanced glycation endproducts.  J Agric Food Chem. 2008;  56 1907-1911
  • 28 Sultana N, Choudhary M I, Khan A. Protein glycation inhibitory activities of Lawsonia inermis and its active principles.  J Enzyme Inhib Med Chem. 2009;  24 257-261
  • 29 Erlund I, Meririnne E, Alfthan G, Aro A. Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice.  J Nutr. 2001;  131 235-241
  • 30 Kale A, Gawande S, Kotwal S, Netke S, Roomi W, Ivanov V, Niedzwiecki A, Rath M. Studies on the effects of oral administration of nutrient mixture, quercetin and red onions on the bioavailability of epigallocatechin gallate from green tea extract.  Phytother Res. 2009;  24 (Suppl. 1) S48-S55
  • 31 Franke A A, Ashburn L A, Kakazu K, Suzuki S, Wilkens L R, Halm B M. Apparent bioavailability of isoflavones after intake of liquid and solid soya foods.  Br J Nutr. 2009;  102 1203-1210
  • 32 Wautier M P, Massin P, Guillausseau P J, Huijberts M, Levy B, Boulanger E, Laloi-Michelin M, Wautier J L. N(carboxymethyl)lysine as a biomarker for microvascular complications in type 2 diabetic patients.  Diabetes Metab. 2003;  29 44-52
  • 33 Fernandez M T, Mira M L, Florencio M H, Jennings K R. Iron and copper chelation by flavonoids: an electrospray mass spectrometry study.  J Inorg Biochem. 2002;  92 105-111
  • 34 Kim D O, Lee C Y. Comprehensive study on vitamin C equivalent antioxidant capacity (VCEAC) of various polyphenolics in scavenging a free radical and its structural relationship.  Crit Rev Food Sci Nutr. 2004;  44 253-273
  • 35 Urios P, Grigorova-Borsos A M, Sternberg M. Flavonoids inhibit the formation of the cross-linking AGE pentosidine in collagen incubated with glucose, according to their structure.  Eur J Nutr. 2007;  46 139-146
  • 36 Baderschneider B, Winterhalter P. Isolation and characterization of novel benzoates, cinnamates, flavonoids, and lignans from Riesling wine and screening for antioxidant activity.  J Agric Food Chem. 2001;  49 2788-2798
  • 37 Matsuda H, Wang T, Managi H, Yoshikawa M. Structural requirements of flavonoids for inhibition of protein glycation and radical scavenging activities.  Bioorg Med Chem. 2003;  11 5317-5323
  • 38 Peyroux J, Sternberg M. Advanced glycation endproducts (AGEs): pharmacological inhibition in diabetes.  Pathol Biol (Paris). 2006;  54 405-419
  • 39 Ferreira M L, Lang G C. Indigenous peoples and diabetes: community empowerment and wellness. Durham, North Carolina; Carolina Academic Press 2006: 549

Dr. John T. Arnason

Department of Biology
Centre for Research in Biopharmaceuticals and Biotechnology
University of Ottawa

30 Marie Curie

Ottawa, Ontario

Canada K1N 6N5

Telefon: + 16 1 35 62 52 62

Fax: + 16 1 35 62 57 65

eMail: John.Arnason@uOttawa.ca